Pulmonary Hypertension - Wesley Research Institute
Wesley Research Institute
Donate
Now
3D Illustration Concept of Human Circulatory System Heart Anatomy

Welcome to the Pulmonary Hypertension Research Program, a research hub that is reshaping the future of pulmonary hypertension treatment. While pulmonary hypertension (PH) currently has no cure, early and tailored treatment has been demonstrated to improve disease management and quality of life. Our research is led by Dr John Feenstra and we are dedicated to finding tailored treatments for this rare and complex disease.

About this research theme

Pulmonary Hypertension is a serious condition characterised by high blood pressure in the blood vessels of the lungs. Unlike regular blood pressure measured in the arm, PH refers to the pressure inside the vessels within the lungs, which can only be confirmed through an invasive procedure. This elevated lung pressure causes patients to feel short of breath and, if left untreated, can ultimately lead to right heart failure and death.

Historically, PH had a very poor prognosis, with patients living just over two years on average. However, the development of new therapies has allowed some patients to now live 10 to 15 years with the condition. The new research program focuses on four major patient groups of Pulmonary Hypertension, addressing a challenge that has long fragmented treatment across different centres.  We aim to provide early treatments, individually tailored to give patients better outcomes.

Comprehensive PH Care

Our research within the Pulmonary Hypertensions Research Program (PHRP) aims to find treatments for a range of PH types:

  • Group 1: Pulmonary artery hypertension (PAH)
  • Group 2: PH due to left-sided heart disease
  • Group 3: PH due to lung disease
  • Group 4: Chronic Thromboembolic Pulmonary Hypertension due to pulmonary artery obstruction (CTEPH)

Each group presents unique challenges and necessitates tailored treatments.  We work with Australian and International experts in the field to bring specialised treatments and early access at the earliest availability for each of the PH types.

Our PHRP Team

We are a team of experienced health professionals who understand the unique experience and challenges of patients with Pulmonary Hypertension, with a referral base across all of Queensland and beyond. Dr John Feenstra’s has extensive involvement in research into pulmonary hypertension and is an expert in PH management. This research program is supported by our team of Wesley Research Institute clinical trial coordinators and doctors.
Our PHRP Team

Pulmonary Hypertension Clinical Trials

CONVERT II

This trial will evaluate lung function changes, hyperinflation (trapped air causing the lungs to become too large), quality of life, and adverse events after the closure of the air channels with the AeriSeal System, followed by the implantation of the Zephyr Valve to achieve bronchoscopic lung volume reduction.  

APEX

The study will help us to understand if TX000045 improves blood flow from the lungs back to the heart, improves filling of participants’ hearts with blood and improves participants’ ability to exercise for patients with Pulmonary Hypertension.

INSIGNIA

This trial is testing a new investigational medication in adults with high blood pressure in the lungs (pulmonary hypertension or PH) related to chronic obstructive pulmonary disease (COPD)

PROSERA

The purpose of this research study is to determine whether seralutanib is safe and effective when given to people with PAH who are already taking other PAH medications.  

TROPOS

The purpose of this study is to determine the safety and effectiveness of a new Pulmonary Artery Hypertension therapy for patients who are already receiving treatment for PAH.
Donate 
to support research
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram